Acrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magovcevic-Liebisch, Ph.D., J.D., to Board of Directors [Yahoo! Finance]
Vigil Neuroscience, Inc. (VIGL)
Company Research
Source: Yahoo! Finance
stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics or AP3, today announced the appointment of Ivana Magovcevic-Liebisch, Ph.D., J.D., to its board of directors. “We are excited to welcome Ivana to our board of directors,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon Therapeutics. “She brings more than 25 years of experience spanning global business and R&D operations, including leading partnering activities, commercialization, research and development, as well as counseling on regulatory, legal and IP strategies. Her diverse and substantial expertise will benefit us as we advance our pipeline of novel compounds.” Dr. Magovcevic-Liebisch is the president and chief executive officer at Vig
Show less
Read more
Impact Snapshot
Event Time:
VIGL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VIGL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VIGL alerts
High impacting Vigil Neuroscience, Inc. news events
Weekly update
A roundup of the hottest topics
VIGL
News
- Vigil Neuroscience, Inc. (NASDAQ: VIGL) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $23.00 price target on the stock.MarketBeat
- Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual MeetingGlobeNewswire
- Vigil Neuroscience, Inc. (NASDAQ: VIGL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $24.00 price target on the stock.MarketBeat
- Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
VIGL
Earnings
- 3/26/24 - Miss
VIGL
Sec Filings
- 4/22/24 - Form ARS
- 4/22/24 - Form DEFA14A
- 4/22/24 - Form DEF
- VIGL's page on the SEC website